Login / Signup

Assessment of mouse VEGF neutralization by ranibizumab and aflibercept.

Yusuke IchiyamaRiko MatsumotoShumpei ObataOsamu SawadaYoshitsugu SaishinMasashi KakinokiTomoko SawadaMasahito Ohji
Published in: PloS one (2022)
Aflibercept but not ranibizumab interacts with mouse VEGF, both in vivo and in vitro. When conducting experiments using anti-VEGF drugs in mice, aflibercept is suitable, but ranibizumab is not.
Keyphrases
  • age related macular degeneration
  • vascular endothelial growth factor
  • endothelial cells
  • diabetic retinopathy
  • type diabetes
  • high fat diet induced
  • insulin resistance
  • optical coherence tomography
  • drug induced